Low libido in women is rarely one thing — but low testosterone is among the most under-tested causes, and testosterone therapy for women with low libido is one of the few interventions backed by randomized controlled trial data.
- Multiple RCTs show testosterone therapy improves satisfying sexual events and desire in women with HSDD.
- Confirm low free testosterone on labs before any prescription; total testosterone alone can read "normal" while free is low.
- Transdermal cream or gel at physiologic female doses is the standard off-label approach, not oral or male-dosed regimens.
- Dosing must target the upper-normal female range, with serum monitoring every 3–6 months in the first year.
- Women in perimenopause, surgical menopause, or natural menopause show the strongest response.
Free testosterone measured by equilibrium dialysis, rather than a calculated estimate, is the marker that correlates with symptoms; calculated free testosterone can underestimate deficiency in women with elevated SHBG.
That is the actual service - not the prescription itself.
TL;DR: Testosterone therapy for women with low libido works — multiple RCTs show meaningful improvement in satisfying sexual events and desire scores in women with hypoactive sexual desire disorder (HSDD). The evidence supports low-dose transdermal testosterone (typically 300 mcg/day patch or equivalent gel), ordered after confirming low free testosterone on labs. GoodLife Health clinicians review labs and build a personalized hormone protocol; the hormone optimization program starts at $179/month. Women in perimenopause, surgical menopause, or natural menopause show the strongest response. If your clinician hasn't tested your testosterone yet, that's the first gap to close in 2026.
Why this matters in 2026
Hypoactive sexual desire disorder affects an estimated 10% of premenopausal women and up to 40% of postmenopausal women, making it the most common female sexual dysfunction in the US. Despite that prevalence, testosterone is not FDA-approved for women — which causes most PCPs to skip the conversation entirely. The result: women with measurably low free testosterone go untreated for years, often told the problem is psychological.
The clinical evidence does not support that default. A 2019 international consensus position statement, endorsed by multiple endocrinology and sexual medicine societies, reviewed 36 RCTs and concluded that transdermal testosterone improves satisfying sexual events, sexual desire, arousal, and orgasm in postmenopausal women. The data for premenopausal women is thinner but directionally consistent.
---
Who this guide is for
This guide is written for adult women — premenopausal, perimenopausal, and postmenopausal — who have noticed a sustained drop in sexual desire that is distressing to them, and who want to understand whether testosterone is a clinically appropriate option before or instead of going through a general practitioner who may have little familiarity with female androgen physiology.
It is also relevant for women already on estrogen or progesterone therapy whose libido has not improved with those hormones alone.
---
What to look for in a testosterone therapy protocol for low libido
1. A baseline free testosterone lab before any prescription
Total testosterone in women is often within "normal" range even when free testosterone is low — because sex hormone-binding globulin (SHBG) can sequester circulating testosterone and make it biologically unavailable. A clinician who orders total testosterone only and calls it normal is missing the relevant number. Free testosterone, measured by equilibrium dialysis rather than calculated estimate, is the marker that correlates with symptoms.
Expect your clinician to order free testosterone, total testosterone, SHBG, and often estradiol in the same panel. In 2026, that panel is accessible through standard labs. GoodLife Health clinicians order and read these labs directly — you are not interpreting ranges alone.
2. Transdermal delivery over oral
Oral testosterone is metabolized by the liver on first pass, which elevates hepatic markers and produces erratic serum levels. The RCT evidence base for female libido — including the APHRODITE and INTIMATE trials — used transdermal patches or gels. Compounded testosterone cream or gel at physiologic female doses (typically 1–5 mg/day) is the standard off-label approach in the US because the 300 mcg/day patch used in trials (Intrinsa) was never approved by the FDA. Your protocol should be transdermal unless there is a documented reason otherwise.
3. Dosing calibrated to female physiology, not male ranges
Women produce roughly 10–20 times less testosterone than men. A protocol that doses based on male reference ranges will produce supraphysiologic levels in women and carry real risks: acne, clitoral sensitivity changes, and — at sustained high levels — irreversible voice deepening or clitoromegaly. The target range for female testosterone therapy is the upper quartile of normal female serum levels, not the lower male range. Any protocol that does not monitor serum levels every 3–6 months in the first year is not being run safely.
4. Symptom-plus-lab confirmation of HSDD
Testosterone therapy for low libido is appropriate when two conditions align: (a) free testosterone is below or in the low-normal female range AND (b) the patient reports distressing reduction in desire with no other clear primary cause. Testosterone is not indicated for relationship distress, medication-induced libido changes (SSRIs, for example, suppress libido through a separate mechanism that testosterone does not fully reverse), or libido reduction in the setting of untreated depression. A clinician who prescribes based on symptoms alone — without labs — is not following the consensus protocol.
5. Coordination with estrogen and progesterone status
In postmenopausal women, low estrogen is typically addressed first. Testosterone added on top of adequate estrogen therapy often produces stronger libido response than either alone. If you are perimenopausal with irregular cycles, progesterone status also matters — low progesterone can blunt libido and mood independently of testosterone. Your hormone panel should include estradiol and progesterone alongside the androgen markers, and your protocol should address all deficiencies, not just the one that showed up first.
6. A monitoring schedule, not a one-time script
Testosterone therapy in women requires follow-up labs at 3–6 weeks after initiation to confirm serum levels are in range, then every 3–6 months during dose optimization, then annually once stable. A protocol that issues a prescription and expects you to self-manage is a liability. The clinician relationship should include lab review at each check-in, dose adjustment capability, and a clear pathway for reporting side effects.
---
Top approaches — evaluated
Compounded testosterone cream or gel — the standard pick
Hook: The workhorse of off-label female testosterone therapy in the US.
Key spec: Typically 1–5 mg/day in a compounded transdermal base; applied to inner arm, inner thigh, or labia minora for higher local absorption.
Concrete number: The 2019 consensus review found women using transdermal testosterone reported an average of 1.2 more satisfying sexual events per 4-week period versus placebo — a clinically meaningful increase in the APHRODITE-class trials.
Verdict: Buy. This is the approach most US clinicians use in 2026 when following the international consensus guidelines. Requires a compounding pharmacy and a clinician who monitors levels. GoodLife Health's hormone optimization program includes the lab review and dosing protocol.
---
Testosterone pellet implants — the wildcard
Hook: A 3–6 month implant placed subcutaneously that delivers steady-state testosterone.
Key spec: Pellets are compounded, typically 12.5–25 mg for women, inserted in a brief office procedure.
Concrete number: Pellet dosing carries a higher documented rate of supraphysiologic testosterone levels than gel — some audits report 30–40% of pellet patients land above the female reference range at peak.
Verdict: Consider with caution. The convenience is real; monitoring is harder because you cannot titrate mid-cycle. Appropriate only with a provider who measures serum levels at 4–6 weeks post-insertion and adjusts the next pellet dose accordingly. Read more about hormone pellet therapy before deciding.
---
DHEA (prasterone) — the adjacent option
Hook: FDA-approved for dyspareunia (vaginal pain with sex), not HSDD — but libido improvement is reported as a secondary benefit.
Key spec: Intrarosa (prasterone 6.5 mg vaginal insert, once daily) converts locally to both estrogen and testosterone in vaginal tissue.
Concrete number: The AMETHYST trial (2016, N=571) showed statistically significant improvement in sexual desire as a secondary endpoint.
Verdict: Hold. Meaningful for women whose primary complaint includes vaginal dryness or pain alongside low libido. Not a replacement for systemic testosterone when HSDD is the central diagnosis.
---
Flibanserin (Addyi) — the FDA-approved alternative
Hook: The only FDA-approved treatment for HSDD in premenopausal women — but not a hormone.
Key spec: A daily oral non-hormonal agent (serotonin/dopamine modulator), 100 mg at bedtime.
Concrete number: NNT (number needed to treat) for one additional satisfying sexual event per month is approximately 10, based on the pivotal trials — modest efficacy versus placebo.
Verdict: Wait. Drug interactions with alcohol and CYP3A4 inhibitors are significant. Consider only if testosterone is contraindicated or trial results are inadequate.
---
What to avoid
- "Hormone optimization" programs that don't run labs first. Any service offering testosterone without ordering baseline free testosterone and SHBG is prescribing blind. This is not a clinical gray area — it is a safety problem.
- Male-dosed testosterone for women. If a prescription reads 50–100 mg/week (standard male dose), the prescriber is not following female androgen protocols. Supraphysiologic androgens in women cause irreversible virilization at sustained levels.
- Treating libido without ruling out depression or medication side effects. SSRIs and SNRIs suppress desire through central serotonergic mechanisms that testosterone does not override. Starting testosterone before addressing medication-induced causes adds an intervention that won't fully work and obscures the root issue.
---
Comparison table
| Approach | Delivery | Dose range (women) | FDA-approved | Level monitoring | Verdict |
|---|---|---|---|---|---|
| Compounded testosterone gel/cream | Transdermal | 1–5 mg/day | No (off-label) | Required q3–6 mo | Buy |
| Testosterone pellets | Subcutaneous implant | 12.5–25 mg/3–6 mo | No (off-label) | Required post-insertion | Consider |
| DHEA / prasterone (Intrarosa) | Vaginal insert | 6.5 mg/day | Yes (dyspareunia) | Not required | Hold |
| Flibanserin (Addyi) | Oral daily | 100 mg/night | Yes (HSDD, premenopausal) | Not required | Wait |
---
FAQ
What is testosterone therapy for women with low libido? It is the use of low-dose exogenous testosterone — typically as a transdermal gel or cream — to restore free testosterone to the upper-normal female range in women with clinically low androgen levels and distressing reduction in sexual desire. It is off-label in the US but supported by over 36 randomized controlled trials as of 2026.
How long does testosterone therapy take to improve libido in women? Most women notice improvement in sexual desire within 4–8 weeks of reaching therapeutic serum levels. Full benefit assessment is typically done at 12 weeks. If no improvement is present by 16 weeks at a confirmed therapeutic level, HSDD may have a different primary driver.
What is a normal testosterone level for women? Free testosterone in adult women runs roughly 0.3–2.2 pg/mL depending on the lab and assay. Total testosterone typically ranges 15–70 ng/dL. The meaningful number is free testosterone measured by equilibrium dialysis — calculated free testosterone can underestimate deficiency in women with elevated SHBG.
Is testosterone therapy safe for women? At doses targeting the upper-normal female range, transdermal testosterone carries a low side-effect burden. The most common issues are acne and mild increases in body hair at initiation. Sustained supraphysiologic dosing — above the female reference range — carries risk of irreversible virilization. This is why serum monitoring is mandatory, not optional.
Can premenopausal women use testosterone for low libido? Yes, though the RCT data is stronger in postmenopausal populations. Premenopausal women with confirmed low free testosterone and HSDD are candidates. The evaluation should also rule out thyroid dysfunction, iron deficiency, and antidepressant use as concurrent causes.
Does testosterone therapy affect mood, energy, or body composition? Yes — often. Secondary benefits reported in clinical data include improved mood, reduced fatigue, and modest improvements in lean mass and fat distribution. These are not guaranteed outcomes and are not the primary indication, but they are consistent enough across RCTs to be clinically relevant.
What labs do I need before starting testosterone therapy? At minimum: free testosterone (equilibrium dialysis), total testosterone, SHBG, estradiol, progesterone (if premenopausal or perimenopausal), TSH, CBC, and a comprehensive metabolic panel. A clinician who starts testosterone without this panel is not following the 2026 consensus standard of care.
How much does testosterone therapy cost for women? Compounded testosterone cream or gel typically costs $40–$90/month at a compounding pharmacy. The clinician relationship — including lab orders, lab review, and dose adjustment — is the larger variable. GoodLife Health's membership covers clinician access, lab review, and protocol management from $179/month.
---
One last thing
The reason most women never get testosterone tested is not medical — it's structural. The standard 15-minute PCP appointment does not have room for a conversation about female androgen physiology, especially when the chief complaint is "low sex drive." The consensus guidelines exist. The lab tests exist. The therapies exist. The gap is a clinician willing to order the panel and read the results in the context of your full hormone picture. That is the actual service — not the prescription itself.
If you want to see how your hormone panel shapes up before committing to a protocol, GoodLife Health clinicians can review your hormone optimization needs and existing labs or order new ones as part of your first visit.
---
Related guides
- Testosterone replacement therapy for women: benefits and risks
- Hormone optimization for women in perimenopause
- Bioidentical hormone replacement therapy for women
- How to know if you need hormone replacement therapy
References
- Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. 2015. doi.org/10.1210/jc.2015-2236
- Testosterone in Women — The Clinical Significance (Lancet Diabetes & Endocrinology). 2015. doi.org/10.1016/S2213-8587(15)00284-300284-3)